N S Sheerin1, D Kavanagh2, T H J Goodship2, S Johnson3. 1. From the Institute of Cellular Medicine, the Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK t.h.j.goodship@ncl.ac.uk. 2. the Institute of Genetic Medicine Newcastle University and the Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK t.h.j.goodship@ncl.ac.uk. 3. the Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK t.h.j.goodship@ncl.ac.uk.
Abstract
BACKGROUND: In 2013 NHS England commissioned the use of eculizumab for both new patients with atypical haemolytic uraemic syndrome (aHUS) and those undergoing transplantation. This national service is delivered locally but coordinated by an expert centre at the Newcastle upon Tyne Hospitals NHS Foundation Trust. RESULTS: In the first year of service, 43 aHUS patients received eculizumab, 15 children and 28 adults. Twenty-three were new patients and 20 prevalent. Fifteen of the 23 new patients required dialysis before eculizumab was started, 8 of these recovered renal function. Twelve of the 20 prevalent patients who received eculizumab were transplant patients, 8 with prophylactic use and 4 for recurrent disease; the outcome in all was good. Eculizumab was withdrawn in 14 patients, 5 were patients who had not recovered renal function. In 3 of the 14 patients, it was necessary to reintroduce eculizumab because of recurrent disease (2 extra-renal and 1 renal). There were 2 deaths in the 43 patients, and neither was associated with use of eculizumab. There were no episodes of meningococcal disease. CONCLUSIONS: The establishment of this national service has enabled aHUS patients in England to receive eculizumab when they need it for as long as they need it.
BACKGROUND: In 2013 NHS England commissioned the use of eculizumab for both new patients with atypical haemolytic uraemic syndrome (aHUS) and those undergoing transplantation. This national service is delivered locally but coordinated by an expert centre at the Newcastle upon Tyne Hospitals NHS Foundation Trust. RESULTS: In the first year of service, 43 aHUS patients received eculizumab, 15 children and 28 adults. Twenty-three were new patients and 20 prevalent. Fifteen of the 23 new patients required dialysis before eculizumab was started, 8 of these recovered renal function. Twelve of the 20 prevalent patients who received eculizumab were transplant patients, 8 with prophylactic use and 4 for recurrent disease; the outcome in all was good. Eculizumab was withdrawn in 14 patients, 5 were patients who had not recovered renal function. In 3 of the 14 patients, it was necessary to reintroduce eculizumab because of recurrent disease (2 extra-renal and 1 renal). There were 2 deaths in the 43 patients, and neither was associated with use of eculizumab. There were no episodes of meningococcal disease. CONCLUSIONS: The establishment of this national service has enabled aHUS patients in England to receive eculizumab when they need it for as long as they need it.
Authors: Shruti Chaturvedi; Noor Dhaliwal; Sarah Hussain; Kathryn Dane; Harshvardhan Upreti; Evan M Braunstein; Xuan Yuan; C John Sperati; Alison R Moliterno; Robert A Brodsky Journal: Blood Adv Date: 2021-03-09
Authors: C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink Journal: Clin Exp Immunol Date: 2016-11-25 Impact factor: 4.330
Authors: Rachel C Challis; Troels Ring; Yaobo Xu; Edwin K S Wong; Oliver Flossmann; Ian S D Roberts; Saeed Ahmed; Michael Wetherall; Giedrius Salkus; Vicky Brocklebank; Julian Fester; Lisa Strain; Valerie Wilson; Katrina M Wood; Kevin J Marchbank; Mauro Santibanez-Koref; Timothy H J Goodship; David Kavanagh Journal: J Am Soc Nephrol Date: 2016-12-14 Impact factor: 10.121
Authors: Alexandra Bruel; David Kavanagh; Marina Noris; Yahsou Delmas; Edwin K S Wong; Elena Bresin; François Provôt; Vicky Brocklebank; Caterina Mele; Giuseppe Remuzzi; Chantal Loirat; Véronique Frémeaux-Bacchi; Fadi Fakhouri Journal: Clin J Am Soc Nephrol Date: 2017-06-08 Impact factor: 8.237